ClinicalTrials.gg
CompletedNCT03015389Updated Jul 23, 2020

Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma

An observational study in Barrett Esophagus, Esophageal Dysplasia and Esophageal Adenocarcinoma, sponsored by CDx Diagnostics. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-23.

Sponsored by CDx Diagnostics · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
170
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-center, prospective, randomized study which will enroll patients undergoing endoscopic surveillance due to a history of histologically confirmed dysplasia. A member of the research team will approach a potential subject to discuss participation in the study, including background of the proposed study, inclusion and exclusion criteria, benefits and risks of the procedures and follow-up. If this is of interest to the subject, the informed consent form is discussed and presented. The subject must sign the consent form prior to enrollment. This form will have prior approval of the study site's Institutional Review Board (IRB). Failure to obtain informed consent renders the subject ineligible for the study.

02

Conditions studied

  • Barrett Esophagus
  • Esophageal Dysplasia
  • Esophageal Adenocarcinoma
03

In context

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

This study's enrollment of 170 is above the median of 144 across 118 observational studies indexed under Barrett Esophagus.

Browse Barrett Esophagus studies →

Lead sponsor

CDx Diagnostics is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Barrett's associated esophageal dysplasia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients age: ≥ 18 years
  2. Patients should have a history of Barrett's associated esophageal dysplasia (either low or high-grade) confirmed on histology
  3. Willingness to undergo both WATS3D and random forceps while undergoing conventional EGD with sedation
  4. Ability to provide written, (approved by IRB) and understand the responsibilities of trial participation
  5. Only patients who no visible mucosal abnormalities at the time that they undergo both random forceps biopsies and WATS3D testing of the esophagus will be included in this study

Exclusion criteria

Exclusion Criteria:

  1. Coagulopathy with > 2.0, thrombocytopenia with counts \< 50,000
  2. The subject is pregnant or planning a pregnancy during the study period
  3. History of esophageal or gastric surgery other than Endoscopic Mucosal Resection (EMR)
  4. Patients who have undergone endoscopic ablative therapies
  5. Subject has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to , post-treatment instructions, or follow-up guidelines
  6. Study patients with inadequate WATS3D specimens will not undergo a repeat brush test and will be excluded from the study
  7. BE length \< 1 cm or > 10 cm
  8. Patients within six weeks of receiving targeted forceps biopsies and/or EMR
  9. Patients with visible mucosal abnormality at the time of the WATS3D and random biopsy testing
  10. Patients with visible lesions that are either submucosal or covered with a clinically intact epithelium
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
170 participants (actual)
Patient registry
No

Groups and cohorts

  • Barrett's associated esophageal dysplasia

    Procedure: Diagnostic Test

Interventions

  • ProcedureDiagnostic Test

    WATS3D brush biopsy

06

What researchers measure

Primary outcomes

  1. Detection rate of Barrett's associated high grade esophageal dysplasia and esophageal adenocarcinoma (HGD/EAC) using WATS3D and random 4 quadrant forceps biopsies taken at 2 cm intervals.

    Time frame: up to 2 years

Secondary outcomes

  1. Number of participants with Barrett's related dysplasia and adenocarcinoma diagnosed with random forceps biopsies and WATS3D biopsies used in alternating fashion.

    Time frame: up to 2 years

07

Study locations

1 site
  • UZ Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Feb 2019, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2017
First posted
Jan 10, 2017
StartActual
Sep 27, 2017
Primary completionActual
Feb 18, 2019
CompletionActual
Feb 18, 2019
Last update
Jul 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03015389
Lead sponsor
CDx Diagnostics
Responsible party
Sponsor
First posted
Jan 10, 2017
Start date
Sep 27, 2017
Primary completion
Feb 18, 2019
Completion
Feb 18, 2019
Last update
Jul 23, 2020

Study contacts

Raf Bisschops, MD
principal investigator · University Hospitals Leuven, Dept. of Gastroenterology
Cesare Hassan, MD
principal investigator · Nuovo Regina Margherita Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion